CD8A and head and neck squamous cell carcinoma: (422), showed that targeting MDSCs with tadalafil (10 mg/day) promotes antitumor immunity by increasing tumor-specific CD8+ T cells in a dose-dependent manner in patients with head and neck squamous cell carcinoma (422).